Patient Guide: A Phase 1b, Randomized, Double-blind, Placebo-controlled Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Oral Doses of SEP-380135 in Adults With Schizophrenia or With a Major Depressive Episode Associated With Bipolar I or II Disorder or Major Depressive Disorder

We'll Help You Connect with This Trial

Quri.ai is a free clinical trial matching service. We help patients like you connect directly with research sites conducting this study.

✓ Get matched to the right study location for you
✓ Connect directly with study coordinators at 1 participating sites
✓ Understand eligibility with our simplified screening tool
✓ Free service - we're here to help you access clinical research

Trial ID: NCTNCT07549581

Status: COMPLETED

Condition: Schizophrenia, Major Depressive Disorder (MDD), Bipolar Disorder

Phase: PHASE1

Find a Study Location Near You

This study is available at 1 research site. We'll help you connect with the location that's right for you.

Participating sites include:

• Los Alamitos, California

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Phase 1b, Randomized, Double-blind, Placebo-controlled Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Oral Doses of SEP-380135 in Adults With Schizophrenia or With a Major Depressive Episode Associated With Bipolar I or II Disorder or Major Depressive Disorder - Join Clinical Trial NCTNCT07549581

How to Join This Clinical Trial - NCTNCT07549581

Learn how to participate in this PHASE1 trial studying SEP-380135 for Schizophrenia, Major Depressive Disorder (MDD), Bipolar Disorder. Current status: COMPLETED.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Schizophrenia, Major Depressive Disorder (MDD), Bipolar Disorder. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied: Schizophrenia, Major Depressive Disorder (MDD), Bipolar Disorder
Treatment Being Tested: SEP-380135
Study Phase: PHASE1 - Early safety study
Enrollment Status: COMPLETED
Study Identifier: NCTNCT07549581 - ClinicalTrials.gov Identifier
Sponsored By: Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

Initial screening to determine eligibility
Regular study visits and health assessments
Receiving the study treatment or placebo
Medical monitoring and follow-up care
Contributing to medical research that may help others
Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

Close medical monitoring by healthcare professionals
Access to potential new treatments
Compensation for time and travel (varies by study)
No-cost study-related medical care
The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 1 locations. Find a study site near you:

Clinical Research Site

Los Alamitos, California - United States

Status: Contact for availability

How to Enroll in This Study

To learn more about participating in this PHASE1 clinical trial for Schizophrenia, Major Depressive Disorder (MDD), Bipolar Disorder:

Review the eligibility criteria with your healthcare provider
Contact the study team for a pre-screening interview
Schedule an in-person screening visit if eligible
Review and sign the informed consent form
Begin participation in the clinical trial

Why Choose Quri.ai as Your Clinical Trial Matching Service

Quri.ai is a free clinical trial matching service that helps patients connect with research sites. We make it easier to:

Find clinical trials that match your condition
Get matched to the right study location near you
Connect directly with study coordinators
Understand if you qualify with simplified eligibility screening
Navigate the enrollment process with personalized support
Access new treatments through clinical research participation